Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Current Deferred Revenue (2023 - 2025)

Monte Rosa Therapeutics' Current Deferred Revenue history spans 3 years, with the latest figure at $29.6 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue fell 74.78% year-over-year to $29.6 million; the TTM value through Dec 2025 reached $29.6 million, down 74.78%, while the annual FY2025 figure was $29.6 million, 74.78% down from the prior year.
  • Current Deferred Revenue reached $29.6 million in Q4 2025 per GLUE's latest filing, down from $111.9 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $117.2 million in Q4 2024 to a low of $17.7 million in Q4 2023.
  • Average Current Deferred Revenue over 3 years is $44.5 million, with a median of $29.6 million recorded in 2025.
  • Peak YoY movement for Current Deferred Revenue: surged 563.15% in 2024, then plummeted 74.78% in 2025.
  • A 3-year view of Current Deferred Revenue shows it stood at $17.7 million in 2023, then soared by 563.15% to $117.2 million in 2024, then tumbled by 74.78% to $29.6 million in 2025.
  • Per Business Quant, the three most recent readings for GLUE's Current Deferred Revenue are $29.6 million (Q4 2025), $111.9 million (Q3 2025), and $18.4 million (Q2 2025).